Holen Sie sich die Stockscreener-App
102.47
0.75%
-0.68
Schlusskurs vom Vortag:
$103.15
Offen:
$102.78
24-Stunden-Volumen:
11,037
Relative Volume:
0.01
Marktkapitalisierung:
$5.94B
Einnahmen:
$360.35M
Nettoeinkommen (Verlust:
$-149.57M
KGV:
-34.62
EPS:
-2.96
Netto-Cashflow:
$-81.27M
1W Leistung:
-11.26%
1M Leistung:
-6.10%
6M Leistung:
+17.04%
1J Leistung:
+4.69%
1-Tages-Spanne:
$101.86
$103.56
1-Wochen-Bereich:
$99.84
$114.40
52-Wochen-Spanne:
$73.16
$130.23
Glaukos Corporation Stock (GKOS) Company Profile
Firmenname
Glaukos Corporation
Sektor
Branche
Telefon
949-367-9600
Adresse
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
102.24 | 5.99B | 360.35M | -149.57M | -81.27M | -2.96 |
|
ABT
Abbott Laboratories
|
110.19 | 192.10B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
355.90 | 137.25B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
89.61 | 115.41B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.67 | 103.81B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
85.31 | 49.82B | 6.07B | 1.06B | 1.34B | 1.8063 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-27 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-10-01 | Eingeleitet | Goldman | Buy |
| 2025-05-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-02-19 | Hochstufung | Mizuho | Neutral → Outperform |
| 2024-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-12-06 | Eingeleitet | UBS | Buy |
| 2024-12-02 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-05-06 | Hochstufung | Jefferies | Hold → Buy |
| 2023-12-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-04 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-11-28 | Eingeleitet | Truist | Buy |
| 2023-11-08 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | Eingeleitet | Mizuho | Neutral |
| 2022-12-19 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-10-14 | Fortgesetzt | Stephens | Overweight |
| 2022-10-04 | Eingeleitet | Needham | Buy |
| 2022-07-12 | Hochstufung | Stifel | Hold → Buy |
| 2022-02-03 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | Hochstufung | BTIG Research | Neutral → Buy |
| 2021-11-03 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-07-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Hochstufung | Citigroup | Sell → Neutral |
| 2020-12-09 | Eingeleitet | Oppenheimer | Perform |
| 2020-11-17 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-06-15 | Eingeleitet | Jefferies | Hold |
| 2020-03-05 | Eingeleitet | Citigroup | Sell |
| 2020-02-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-01-06 | Hochstufung | Berenberg | Hold → Buy |
| 2019-12-12 | Herabstufung | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | Eingeleitet | BTIG Research | Neutral |
| 2018-08-30 | Eingeleitet | Berenberg | Hold |
| 2018-08-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-08-03 | Bestätigt | Stifel | Hold |
| 2018-06-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-04-13 | Herabstufung | Stifel | Buy → Hold |
| 2018-03-01 | Bestätigt | Cantor Fitzgerald | Buy |
| 2017-03-02 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-01-06 | Hochstufung | Stifel | Hold → Buy |
| 2016-10-27 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Glaukos Corporation Aktie (GKOS) Neueste Nachrichten
Zacks Research Weighs in on Glaukos FY2028 Earnings - MarketBeat
Canaloplasty Market Is Going to Boom |• Glaukos Corporation • Aquesys Inc - openPR.com
(GKOS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Performance Recap: Is Glaukos Corporation affected by consumer sentimentJuly 2025 News Drivers & AI Forecasted Stock Moves - baoquankhu1.vn
TD Asset Management Inc Takes Position in Glaukos Corporation $GKOS - MarketBeat
Glaucoma Surgery Device Market Is Going to Boom | Glaukos Corporation • Santen Pharmaceutical • Carl Zeiss AG - openPR.com
Glaukos Corporation $GKOS Shares Purchased by AustralianSuper Pty Ltd - MarketBeat
Should You Buy Glaukos Corp (GKOS) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
Glaukos’ 2025 Loss, Impairment and ESOP Shelf Might Change The Case For Investing In GKOS - simplywall.st
Glaukos Corporation (GKOS) Stock Analysis: Potential 11.95% Upside Amid Robust Revenue Growth - DirectorsTalk Interviews
William Blair Investment Management LLC Has $89.20 Million Holdings in Glaukos Corporation $GKOS - MarketBeat
Glaukos Highlights Interventional Ophthalmology Strategy in Investor Update - TipRanks
Glaukos : Investor Presentation March 2026 - marketscreener.com
Glaukos unveils March 2026 investor presentation highlighting iDose TR approval, Epioxa launch and 2026 $610M sales guide - TradingView
Glaukos (GKOS) furnishes March 2026 Investor Presentation for stakeholders - Stock Titan
DNB Asset Management AS Purchases 16,267 Shares of Glaukos Corporation $GKOS - MarketBeat
GKOS SEC FilingsGlaukos Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Glaukos Refines Glaucoma Implant Delivery With New Inserter Study - TipRanks
Primecap Management Co. CA Grows Stake in Glaukos Corporation $GKOS - MarketBeat
Fox Run Management L.L.C. Purchases Shares of 12,308 Glaukos Corporation $GKOS - MarketBeat
Glaukos Expands Eye Care Pipeline With New GLK-321 Trial in Demodex Blepharitis - TipRanks
Glaukos : Statement of Changes in Beneficial Ownership (Form 4) - marketscreener.com
Glaukos (NYSE: GKOS) CEO has 4,059 shares withheld to cover taxes - Stock Titan
Glaukos (NYSE: GKOS) CDO reports 396-share tax-withholding disposition - Stock Titan
GLAUKOS (GKOS) COO’s RSU vesting triggers 1,057-share tax withholding - Stock Titan
Glaukos Corporation $GKOS Shares Acquired by Westfield Capital Management Co. LP - MarketBeat
21,717 Shares in Glaukos Corporation $GKOS Acquired by Zhang Financial LLC - MarketBeat
Glaukos Corporation $GKOS Stock Holdings Decreased by Vanguard Group Inc. - MarketBeat
JPMorgan Chase & Co. Acquires 27,646 Shares of Glaukos Corporation $GKOS - MarketBeat
Should Glaukos’ (GKOS) Big 2026 Sales Target and ESOP Shelf Filing Require Action From Investors? - Yahoo Finance
(GKOS) Risk Channels and Responsive Allocation - Stock Traders Daily
GKOS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Glaukos Corp. Experiences Revision in Its Stock Evaluation Amid Financial Performance Trends - Markets Mojo
AI Adoption Raises Operational, Regulatory, and Reputational Risks for Glaukos Corp. - TipRanks
Insider Selling: Glaukos (NYSE:GKOS) Director Sells 15,000 Shares of Stock - MarketBeat
Glaukos (GKOS) director exercises 15K options and sells 15K shares - Stock Titan
Glaukos Corporation (GKOS) Stock Analysis: Strong Buy Ratings and a Potential 12% Upside for This Medical Device Innovator - DirectorsTalk Interviews
Strong Results with 38.1% Revenue Growth Lifted Glaukos (GKOS) in Q4 - Bitget
Granite Investment Partners LLC Sells 55,233 Shares of Glaukos Corporation $GKOS - MarketBeat
GLAUKOS Corp SEC 10-K Report - TradingView
Glaukos (GKOS) Is Up 9.9% After Issuing Robust 2026 Sales Outlook Amid Net Losses – What's Changed - simplywall.st
Moving Averages: Is Glaukos Corporation trading at a discountMarket Sentiment Summary & Weekly Return Optimization Plans - baoquankhu1.vn
Glaukos Corporation (NYSE:GKOS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Can Glaukos Corporation stock hit record highs again2025 Momentum Check & Free Long-Term Investment Growth Plans - mfd.ru
Glaukos (NYSE:GKOS) Cut to "Hold" at Wall Street Zen - MarketBeat
Glaukos Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
Glaukos Stock Jumps 13% After Q4 Beat: Here’s What Its 2026 Guidance Signals - TIKR.com
Glaukos stock steadies premarket after a 13% surge — what GKOS investors watch next - Bez Kabli
Needham raises Glaukos stock price target on iDose, Epioxa growth By Investing.com - Investing.com India
Needham raises Glaukos stock price target on iDose, Epioxa growth - Investing.com Nigeria
Why Analysts See Glaukos (GKOS) Story Shifting As iDose Repeat Dosing Takes Center Stage - Yahoo Finance
Finanzdaten der Glaukos Corporation-Aktie (GKOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.23%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):